BNR
Burning Rock Biotech Ltd
NASDAQ: BNR · HEALTHCARE · DIAGNOSTICS & RESEARCH
$17.00
+4.68% today
Updated 2026-04-30
Market cap
$222.76M
P/E ratio
—
P/S ratio
0.41x
EPS (TTM)
$-0.75
Dividend yield
—
52W range
$2 – $42
Volume
0.0M
Burning Rock Biotech Ltd (BNR) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$17.00
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$256.22
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.5B | $0.6B | $0.5B | $0.5B | $0.5B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -10.30%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.